The Efficacy And Safety Of Mitizodone Phosphate Tablets In The Treatment of Patient With Major Depressive Disorder
20 augusti 2026 uppdaterad av: Sunshine Lake Pharma Co., Ltd.
A Phase II/III ,Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Adaptive Design Study Evaluating the Efficacy And Safety of Mitizodone Phosphate Tablets in the Treatment of Patient With Major Depressive Disorder
This is a phase 2 and 3 adaptive design study for Mitizodone Phosphate,to find out an optimal dose in phase 2 period and confirm the result an efficacy and safety in phase 3 period.Dose-finding will be done after 8 weeks of double-blinded treatment in phase 2 period and will be assessed by both efficacy and safety from 3 dose groups of Mitizodone Phosphate.The dose be found in phase 2 period will be evaluated on efficacy and safety when compared with placebo in phase 3 period with a duration of 8 weeks treatment.The target subjects are patients with MDD.
Studieöversikt
Status
Rekrytering
Betingelser
Intervention / Behandling
Studietyp
Interventionell
Inskrivning (Beräknad)
600
Fas
- Fas 2
- Fas 3
Kontakter och platser
Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.
Studiekontakt
- Namn: gang wang, Ph.D
- Telefonnummer: 86-010-58303236
- E-post: gangwangdoc@gmail.com
Studieorter
-
-
Guangdong
-
Dongguan, Guangdong, Kina, 523871
- Rekrytering
- Sunshine Lake Pharma Co., Ltd.
-
Kontakt:
- Li Xue
- Telefonnummer: +8676985315888
- E-post: lixuelc@hec.cn
-
-
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
18 år till 65 år (Vuxen, Äldre vuxen)
Tar emot friska volontärer
Nej
Beskrivning
Inclusion Criteria:
- 1.a Man or a woman with major depressive disorder(MDD) as the primary diagnosis according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria (classification code 296.22、296.23、296.32、296.33)
- 2.Has a Montgomery Åsberg Depression Rating Scale (MADRS) total score of 26 or greater at Screening and Baseline Visits.
- 3.Has a Clinical Global Impression - Severity of Illness (CGI-S) score of 4 or greater at Screening and Baseline Visits.
Exclusion Criteria:
- 1.has major depressive disorder with psychotic features according to the DSM-5.
- 2.Current or history of: bipolar disorder、schizophrenia、anixety disorder、insomnia、any substance abuse or dependence and other psychiatry disorder as defined in the DSM-5.
- 3.Current or history of a clinically significant neurological disorder (including epilepsy、Alzheimer disease, Parkinson disease, multiple sclerosis, Huntington disease).
- 4. has Serious body disease such as neurological disorders、cardiacvascular disorders、hepatic disorders、 renal disorders, blood system disorders and endocrine disorders.
- 5. Current or history of cancer( except basal cell of the skin and preinvasive carcinoma of cervix uteri).
- 6. Current or history of angle-closure glaucoma.
- 7. has made a suicide behavior in the previous 1 year ，or has a score greater than or equal to 4 on item 10 (suicidal thoughts) of MADRS .
- 8.has taken fluoxetine within 4 weeks prior to initial dosing.
- 9. has taken other antidepressive medications or antipsychotic medications within 2 weeks prior to initial dosing.
- 10.has psychotherap at Screening and/or Baseline Visits.
- 11.has had physiotherapy within 3 months prior to initial dosing.
- 12.Has an alanine aminotransferase, aspartate aminotransferase or total bilirubin level greater than 1.5 times the upper limits of normal.
- 13.Has an alanine aminotransferase, aspartate aminotransferase level greater than 2 times the upper limits of normal；or total bilirubin， direct bilirubin，creatinine level greater than 1.5 times the upper limits of normal；or a thyroid stimulating hormone value outside the normal range.
- 14.Has an abnormal electrocardiogram confirmed as clinically significant by the investigator.
- 15.Has a history of severe allergies.
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Fyrdubbla
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Mitizodone Phosphate tablet 10mg
Mitizodone Phosphate tablet 10mg ,orally,once daily for 8 weeks, then placebo,orally,once daily for 2 weeks.
|
Mitizodone Phosphate tablets will be administered with food.
Andra namn:
|
|
Experimentell: Mitizodone Phosphate tablet 20mg
Mitizodone Phosphate tablet 10mg ,orally,once daily for 1 weeks, then Mitizodone Phosphate tablet 20mg ,orally,once daily for 7 weeks, then Mitizodone Phosphate tablet 10mg ,orally,once daily for 1 weeks, then placebo,orally,once daily for 1 weeks.
|
Mitizodone Phosphate tablets will be administered with food.
Andra namn:
|
|
Experimentell: Mitizodone Phosphate tablet 40mg
Mitizodone Phosphate tablet 10mg ,orally,once daily for 1 weeks, then Mitizodone Phosphate tablet 20mg ,orally,once daily for 1 weeks, then Mitizodone Phosphate tablet 40mg ,orally,once daily for 6 weeks, then Mitizodone Phosphate tablet 20mg ,orally,once daily for 1 weeks, then Mitizodone Phosphate tablet 10mg ,orally,once daily for 1 weeks.
|
Mitizodone Phosphate tablets will be administered with food.
Andra namn:
|
|
Aktiv komparator: Placebo
Placebo,tablet,orally,once daily for 10 weeks.
|
Placebo will be administered with food.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Change From Baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score at week 8
Tidsram: baseline and week 8
|
The MADRS is a depression rating scale consisting of 10 items, each rated 0 (normal) to 6 (most abnormal).
The 10 items represent the core symptoms of depressive illness.
The overall score ranges from 0 (symptoms absent) to 60 (severe depression).
A decrease in the total score or on individual items indicates improvement.
|
baseline and week 8
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Percentage of subjects With a MADRS Response at Week 8
Tidsram: baseline and week 8
|
Response is defined as a subject with a ≥50% decrease in Montgomery Åsberg Depression Rating Scale (MADRS) total score from Baseline.
|
baseline and week 8
|
|
Percentage of Participants in MADRS Remission at Week 8
Tidsram: week 8
|
Remission is defined as a participant with a Montgomery Åsberg Depression Rating Scale (MADRS) total score ≤10.
|
week 8
|
|
Change From Baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score at week 1、week 2 、week 4、week 6.
Tidsram: baseline 、 week 1、week 2 、week 4 and week 6.
|
The MADRS is a depression rating scale consisting of 10 items, each rated 0 (normal) to 6 (most abnormal).
The 10 items represent the core symptoms of depressive illness.
The overall score ranges from 0 (symptoms absent) to 60 (severe depression).
A decrease in the total score or on individual items indicates improvement.
|
baseline 、 week 1、week 2 、week 4 and week 6.
|
|
Change From Baseline in the Clinical Global Impression - Severity of illness (CGI-S) Total Score at week 1、week 2 、week 4、week 6、week 8.
Tidsram: baseline、week 1、week 2 、week 4、week 6 and week 8.
|
The Clinical Global Impression-Severity of illness scale assesses the subject's Severity as assessed by the clinician at the moment on a 8-point scale: 0, not assessed ; 1, normal，not at all ill ; 2, borderline mentally ill ; 3, mildly ill ; 4, moderately ill ; 5 , markedly ill ; 6, severely ill；7，among the most extremely ill patients.
|
baseline、week 1、week 2 、week 4、week 6 and week 8.
|
|
Clinical Global Impression - Improvement (CGI-I) Score at week 1、week 2 、week 4、week 6、Week 8
Tidsram: week 1、week 2 、week 4、week 6 and week 8.
|
The Clinical Global Impression- Improvement scale assesses the subject's improvement (or worsening) as assessed by the clinician relative to Baseline on a 8-point scale: 0, not assessed ;1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse.
|
week 1、week 2 、week 4、week 6 and week 8.
|
|
Change From Baseline in the hamilton anxiety rating scale （HAM-A）Total Score at week 1、week 2 、week 4、week 6、week 8.
Tidsram: baseline、week 1、week 2 、week 4、week 6 and week 8.
|
the HAM-A is a anxiety rating scale consisting of 14 items, each rated 0 (none) to 4 (very severe).
The 14 items represent the core symptoms of anxiety illness.
The overall score ranges from 0 (symptoms absent) to 56 (severe anxiety).
A decrease in the total score or on individual items indicates improvement.
|
baseline、week 1、week 2 、week 4、week 6 and week 8.
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Sponsor
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart (Faktisk)
14 december 2021
Primärt slutförande (Beräknad)
1 juli 2027
Avslutad studie (Beräknad)
1 november 2027
Studieregistreringsdatum
Först inskickad
21 juli 2021
Först inskickad som uppfyllde QC-kriterierna
21 juli 2021
Första postat (Faktisk)
30 juli 2021
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
24 augusti 2026
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
20 augusti 2026
Senast verifierad
1 augusti 2026
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- HEC113995-P-5
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
NEJ
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Nej
Studerar en amerikansk FDA-reglerad produktprodukt
Nej
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .